Morphosys Ag

Novartis Ag

Lanthiopep B.v.

Mor0059us.np

Adivo Gmbh

Novartis Pharma Gmbh

Mereo Biopharma 3 Limited

Morphosys IP Gmbh

Josef Prassler

Thomas Tiller

Markus Enzelberger

Yvonne Stark

Stefanie Urlinger

Shou-Ih Hu

Kathrin Ladetzki-Baehs

Beate Diefenbach-Streiber

Tanja Herrmann

Markus Waldhuber

Markus Moosmeier

Stefanie Thiel

Christine Halleux

Ralf Strohner

Hilmar Erhard Ebersbach

Thomas Pietzonka

Andreas Bültmann

David Ott

Roger Müller

Ute Keck

Michaela Kniessel

Christine Rothe

Andreas Menrad

Ingo Klagge

David Raymond Stover

Michaela Kneissel

Tjibbe Bosma

Catrin Berger

William Leonard Wishart

Bodo Brocks

Armin Weidmann

Johannes Herbert Urban

Stefanie Urlnger

Adrian Walmsley

Marta Cortes-Cros

Markus Andreas Moosmeier

Roger MÜLLER

Adrian Robert Walmsley

The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.

Canine antibody libraries

The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.

Polypeptide library

The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.

Rodent combinatorial antibody libraries

The present invention relates to methods for displaying cyclic peptides on the surface of bacteriophage particles and collections thereof.

Methods for displaying cyclic peptides on bacteriophage particles

The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.

Collection and methods for its use

The present invention relates to methods for the formation of inter-molecular disulphide bonds, including (poly)peptides/proteins, nucleic acids, vectors, host cells and bacteriophages used in these methods. Furthermore the invention relates to the use of this method for the improved display of (poly)peptides/proteins on the surface of bacteriophage particles.

Methods for the formation of disulphide bonds

The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.

Polynucleotides encoding antibodies against sclerostin and uses therefor

The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, and a polynucleotide encoding the binding molecule. The invention also provides an expression vector comprising the polynucleotide, an expression system comprising a polynucleotide capable of producing a binding molecule, as well as an isolated host cell comprising the expression system for producing the binding molecule. The invention also provides for compositions comprising the LINGO binding molecules and the use of binding molecule compositions as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity. The invention further provides for a method of treatment of diseases associated with axonal degeneration and demyelination.

LINGO binding molecules and pharmaceutical use thereof

The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR) members, where diversity of the collection is a function of the length of the HCDRmembers. The diversity of the collection of HCDRregions substantially represents the natural amino acid distribution of HCDRin the human repertoire. This natural amino acid distribution can be represented by biasing the complete random distribution of amino acids, accordingly, in the HCDRencoding DNA sequence by using trinucleotide mutagenesis (TRIM) technology. A collection of HCDRmembers of the invention each can be comprised within a variable region of an antibody (or fragment thereof) to form a library of synthetic antibodies or antibody fragments. The invention also provides nucleic acid molecules encoding such diverse collection and methods of making and using the same.

Collection of HCDR3 regions and uses therefor

Growing community of inventors

Germering, Germany

Josef Prassler